First-Line Atezolizumab Effective in Bladder Cancer.

Aún no traducido Aún no traducido
Autores
Categoría Estudio primario
RevistaCancer discovery
Año 2016
Results from a phase II study indicate that the PD-L1 inhibitor atezolizumab, recently approved for advanced bladder cancer that's refractory to standard platinum chemotherapy, is effective as first-line therapy for this disease. Durable responses to atezolizumab were seen in nearly a quarter of the study patients, who were all ineligible to receive cisplatin.
Epistemonikos ID: a843efa231ec9c98fedaf222a70c5a7abc0a699b
First added on: Oct 27, 2017